Overview

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia

Phase:

Phase 4

Details

Lead Sponsor:

GeneScience Pharmaceuticals Co., Ltd.

Collaborators:

Chengdu Women's and Children's Central Hospital
Children's Hospital of Fudan University
Children's Hospital of Nanjing Medical University
Children's Hospital of The Capital Institute of Pediatrics
Jiangxi Province Children's Hospital
Shandong Provincial Hospital
Shanghai Children's Hospital
Shengjing Hospital
Tongji Hospital

Treatments:

Hormones